This study evaluates conversion therapy outcomes in patients with unresectable esophageal squamous cell carcinoma, suggesting clinical efficacy in them.
Key Points
The conversion rate for unresectable esophageal squamous cell carcinoma reached 56%, indicating treatment potential.
R0 resection was achieved in 64.3% of patients undergoing thoraco-laparoscopic esophagectomy after conversion therapy.
Preoperative therapy included immunotherapy and chemotherapy, followed by surgery to assess clinical efficacy and safety.
With a median follow-up of 13.2 months, the findings support ongoing exploration of this treatment approach.